| Update on the pharmacologic management of overactive bladder: the present and the future. | |
| | |
MedLine Citation:
|
PMID: 20359143 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Overactive bladder (OAB) is a common condition, affecting approximately 17% of females and males 40 years of age and older. Historically, oxybutynin was the only medication approved for use in the management of OAB. Over the past decade, several new antimuscarinics have been approved for the treatment of OAB. Although all are deemed to be effective in improving the bothersome symptoms of OAB, they differ in their molecular properties, metabolism, and tolerability/side effect profile. A greater understanding of the pathophysiology of OAB has led to approved and investigative therapies to treat refractory OAB, such as neuromodulation and intravesical injection of Botulinum toxin, respectively. A variety of pharmacologic agents are in clinical trials for OAB that target different components of bladder function, such as the urothelium, the afferent sensory nerve pathways, and the central nervous system. It is the intent of this article to highlight these aspects of OAB management. |
| | |
Authors:
|
Pamela Ellsworth; Eileen Kirshenbaum |
Related Documents
:
|
19030763 - Nonsurgical management of the neurogenic bladder in children. 19503763 - Update on duloxetine for the management of stress urinary incontinence. 10474143 - Diagnostic statistical procedures in medical meta-analyses. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Urologic nursing Volume: 30 ISSN: 1053-816X ISO Abbreviation: Urol Nurs Publication Date: 2010 Jan-Feb |
Date Detail:
|
Created Date: 2010-04-02 Completed Date: 2010-05-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8812256 Medline TA: Urol Nurs Country: United States |
Other Details:
|
Languages: eng Pagination: 29-38, 53 Citation Subset: N |
Affiliation:
|
The Warren Alpert Medical School, Brown University Providence, RI, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Behavior Therapy Causality Cost of Illness Drug Approval Female Forecasting Humans Male Medication Adherence Muscarinic Antagonists / adverse effects, metabolism, pharmacology, therapeutic use Prevalence Quality of Life United States / epidemiology Urinary Bladder, Overactive / diagnosis, drug therapy*, epidemiology World Health |
| Chemical | |
Reg. No./Substance:
|
0/Muscarinic Antagonists |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Individual variations in drug responses.
Next Document: New therapeutic strategies for renal cell carcinoma.